SLC5A2 and metabolic dysfunction-associated steatotic liver disease: The meta-analysis showed that SGLT2 inhibitors significantly reduced the AST levels in patients with NAFLD (WMD -2.57 [95% CI: -3.84, -1.30], p < 0.0001).